FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2781426917> ?p ?o ?g. }

• W2781426917 endingPage "428" @default.
• W2781426917 startingPage "423" @default.
• W2781426917 abstract "Currently, the role of dacarbazine (DTIC) based chemotherapy in neuroendocrine tumors (NETs) in Asia is unclear. Here, we report the outcomes of dacarbazine (DTIC)-based chemotherapy in Taiwan population.DTIC alone (250 mg/m2/day), or 5-fluorouracil (5-FU, 500 mg/m2/day) and DTIC (200 mg/m2/day) with or without epirubicin (200 mg/m2/day), for 3 days, every 3-4 weeks. Subgroups were analyzed by grading, and by Ki-67 index.48 patients were reviewed in this study, including 3 had grade 1 tumors, 23 had grade 2, while 22 were grade 3. In grade 3 NEC patients, the tumor Ki-67 index of 21-55% were noted in 8 patients, and >55% in 14 patients. Progression-free survival (PFS) was 5.1 months, and overall survival (OS) was 31.6 months. The PFS (in months) were 12.5 and 1.8 for patients with NETs and neuroendocrine carcinomas (NECs), respectively (p < 0.001). The OS were not reached and 5.9 months for patients with NETs and NECs, respectively (p = 0.001). Patients with NECs were divided into two groups, according to their Ki-67 index. In patients with a tumor Ki-67 index of 21-55%, PFS was 4.1 months, and OS was not reached; in those with a tumor Ki-67 index of >55%, they were 1.5 and 1.8 months, respectively (p < 0.001 and p = 0.013).NETs, and grade 3 NECs, with Ki-67 indices of 20-55% had good responses to DTIC-based chemotherapy, with acceptable side effects. Ki-67 index could predict prognosis for grade 3 NEC patients, and guide further chemotherapy choices." @default.
• W2781426917 created "2018-01-05" @default.
• W2781426917 creator A5007383914 @default.
• W2781426917 creator A5026090288 @default.
• W2781426917 creator A5026375714 @default.
• W2781426917 creator A5027932918 @default.
• W2781426917 creator A5032784258 @default.
• W2781426917 creator A5036469662 @default.
• W2781426917 creator A5038618545 @default.
• W2781426917 creator A5061617113 @default.
• W2781426917 creator A5081324524 @default.
• W2781426917 creator A5083099346 @default.
• W2781426917 creator A5088367963 @default.
• W2781426917 creator A5091303402 @default.
• W2781426917 date "2018-05-01" @default.
• W2781426917 modified "2023-10-17" @default.
• W2781426917 title "Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population" @default.
• W2781426917 cites W1917632054 @default.
• W2781426917 cites W1941794935 @default.
• W2781426917 cites W1964586919 @default.
• W2781426917 cites W1975286626 @default.
• W2781426917 cites W1995681258 @default.
• W2781426917 cites W1996180982 @default.
• W2781426917 cites W2045173749 @default.
• W2781426917 cites W2046240033 @default.
• W2781426917 cites W2050942858 @default.
• W2781426917 cites W2079144528 @default.
• W2781426917 cites W2079643523 @default.
• W2781426917 cites W2081457024 @default.
• W2781426917 cites W2100030097 @default.
• W2781426917 cites W2107276199 @default.
• W2781426917 cites W2144637780 @default.
• W2781426917 cites W2144654767 @default.
• W2781426917 cites W2145529793 @default.
• W2781426917 cites W2149214723 @default.
• W2781426917 cites W2161676563 @default.
• W2781426917 cites W2170518806 @default.
• W2781426917 cites W2227093581 @default.
• W2781426917 doi "https://doi.org/10.1016/j.jcma.2017.08.020" @default.
• W2781426917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29287706" @default.
• W2781426917 hasPublicationYear "2018" @default.
• W2781426917 type Work @default.
• W2781426917 sameAs 2781426917 @default.
• W2781426917 citedByCount "1" @default.
• W2781426917 countsByYear W27814269172019 @default.
• W2781426917 crossrefType "journal-article" @default.
• W2781426917 hasAuthorship W2781426917A5007383914 @default.
• W2781426917 hasAuthorship W2781426917A5026090288 @default.
• W2781426917 hasAuthorship W2781426917A5026375714 @default.
• W2781426917 hasAuthorship W2781426917A5027932918 @default.
• W2781426917 hasAuthorship W2781426917A5032784258 @default.
• W2781426917 hasAuthorship W2781426917A5036469662 @default.
• W2781426917 hasAuthorship W2781426917A5038618545 @default.
• W2781426917 hasAuthorship W2781426917A5061617113 @default.
• W2781426917 hasAuthorship W2781426917A5081324524 @default.
• W2781426917 hasAuthorship W2781426917A5083099346 @default.
• W2781426917 hasAuthorship W2781426917A5088367963 @default.
• W2781426917 hasAuthorship W2781426917A5091303402 @default.
• W2781426917 hasBestOaLocation W27814269171 @default.
• W2781426917 hasConcept C126322002 @default.
• W2781426917 hasConcept C127413603 @default.
• W2781426917 hasConcept C143998085 @default.
• W2781426917 hasConcept C147176958 @default.
• W2781426917 hasConcept C204232928 @default.
• W2781426917 hasConcept C2776694085 @default.
• W2781426917 hasConcept C2776755627 @default.
• W2781426917 hasConcept C2777286243 @default.
• W2781426917 hasConcept C2777751288 @default.
• W2781426917 hasConcept C2779066768 @default.
• W2781426917 hasConcept C2780456651 @default.
• W2781426917 hasConcept C2780739268 @default.
• W2781426917 hasConcept C2780835546 @default.
• W2781426917 hasConcept C2780964509 @default.
• W2781426917 hasConcept C2908647359 @default.
• W2781426917 hasConcept C71924100 @default.
• W2781426917 hasConcept C90924648 @default.
• W2781426917 hasConcept C99454951 @default.
• W2781426917 hasConceptScore W2781426917C126322002 @default.
• W2781426917 hasConceptScore W2781426917C127413603 @default.
• W2781426917 hasConceptScore W2781426917C143998085 @default.
• W2781426917 hasConceptScore W2781426917C147176958 @default.
• W2781426917 hasConceptScore W2781426917C204232928 @default.
• W2781426917 hasConceptScore W2781426917C2776694085 @default.
• W2781426917 hasConceptScore W2781426917C2776755627 @default.
• W2781426917 hasConceptScore W2781426917C2777286243 @default.
• W2781426917 hasConceptScore W2781426917C2777751288 @default.
• W2781426917 hasConceptScore W2781426917C2779066768 @default.
• W2781426917 hasConceptScore W2781426917C2780456651 @default.
• W2781426917 hasConceptScore W2781426917C2780739268 @default.
• W2781426917 hasConceptScore W2781426917C2780835546 @default.
• W2781426917 hasConceptScore W2781426917C2780964509 @default.
• W2781426917 hasConceptScore W2781426917C2908647359 @default.
• W2781426917 hasConceptScore W2781426917C71924100 @default.
• W2781426917 hasConceptScore W2781426917C90924648 @default.
• W2781426917 hasConceptScore W2781426917C99454951 @default.
• W2781426917 hasFunder F4320324350 @default.
• W2781426917 hasIssue "5" @default.
• W2781426917 hasLocation W27814269171 @default.

• next